Page last updated: 2024-12-05

meprobamate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Meprobamate is a medication used to treat anxiety disorders. It was first synthesized in 1950 by Dr. Frank M. Berger and was marketed under the brand name Miltown. Meprobamate is a carbamate derivative and acts as a central nervous system depressant. It is believed to exert its effects by enhancing the activity of the neurotransmitter GABA, which has calming and sedative effects. Meprobamate is a Schedule IV controlled substance in the United States, meaning it has a low potential for abuse and dependence. It is generally well-tolerated but can cause side effects such as drowsiness, dizziness, and nausea. Meprobamate was widely used in the 1950s and 1960s as a treatment for anxiety and insomnia, but its use has declined in recent years due to the development of safer and more effective medications. Research on meprobamate continues to focus on its potential for treating other conditions, such as epilepsy and alcohol withdrawal. While meprobamate remains an option for some individuals with anxiety disorders, it is not typically considered a first-line treatment.'

Meprobamate: A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of ANXIETY DISORDERS, and also for the short-term management of INSOMNIA but has largely been superseded by the BENZODIAZEPINES. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4064
CHEMBL ID979
CHEBI ID6761
SCHEMBL ID15286
MeSH IDM0013438

Synonyms (351)

Synonym
meprobamate
fas-cile
meprocon
cap-o-tran
coprobate
1,3-propanediol, 2-methyl-2-propyl-, dicarbamate
miltaun
aneural
restenyl
anastress
ipsotian
meptranactylmilprem
biobamate
erina
ansiatan
kesso-bamate
milprem
meprosin
meproleaf
metranquil
1, 2-methyl-2-propyl-, dicarbamate
miltown
meprocon cmc
meprol
tensonal
miltuan
nsc-30418
solevione anastress
meprotabs
anathylmon
pan-tranquil
amepromat
tranquilan
component of milprem
margonil
pancalma
sk-bamate
epikur
miltann
klort
perequietil
ayeramate
meprospan
tranquiline (intra)
stensolo
sedanil
cypron
probamyl
cirponyl
estasil
paxin
dapaz
bamo 400
urbil
procalmadol
3p bamate
misedant
amosene
carbaxin
pankalma
procalmidol
enorden
meprosan
ecuanil
anxietil
probamato
fas-cile 200
meproban
auxietil
meprindon
tranquilate
quanane
perquietil
mepamtin
carbamic acid, 2-methyl-2-propyltrimethylene ester
ataraxine
shalvaton
libiolan
bamd 400
component of pmb-400
kessobamate
seril
equatrate
pertranquil
meprotil
mar-bate
edenal
brobamate
sedanyl
pensive
aneuxal
procarbamide
calmax
ansietan
setran
gadexyl
mendel
meprobam
ansil
anatimon
urbilat
equanil
mepranil
meprotan
nsc30418
dicandiol
2-methyl-2-n-propyl-1,3-propanediol dicarbamate
meprin
scolazil
hartol
atraxin
despasmol
meprovanmeprozine
andaksin
optarket
restinal
crestanil
canquil 400
equilium
epicur
panediol
lepenil
ansiowas
andaxin
trelmar
trankvilan
quanil
anural
gagexyl
vio-bamate
holbamate
metractyl
rastenil
tensol
multaun
prequil
2,2-di(carbamoyloxymethyl)pentane
sedoselecta
promato
meprocompren
procalmadiol
sadanyl
miltwon
placidon
wardamate
neuramate
tranquiline
restenil
arcoban
calmiren
aneuxral
ayermate
meprosa
wln: zvo1x3&1&1ovz
meptran
tranlisant
equinil
tranquilsan
diurnaldiverondormabrol
mepiosine
57-53-4
anzil
artolon
selene
arpon
promate
carbamic acid 2-methyl-2-propyltrimethylene ester
component of equalysen
lepetown
meprodil
aneurol
oasil
sedoquil
quivet
proquanil
equitar
miltamato
component of miltrate
zirpon
wyseals
quietidon
quaname
diron
nephentine
vistabamate
mepavlon
spantran
tranquilax
harmonin
robamate
component of milpath
tamate
tranmep
nervonus
tranquinol
mepriam
morbam
meposed
placitate
apasil
neo-tran
biobamat
protran
mepantin
orlevol
letyl
larten
apascil
reostral
sedazil
aneusral
sowell
equanil suspension
calmadin
perequil
restinil
orolevol
pimal
cirpon
canquil-400
cyrpon
sedabamate
meprobamat
2-[(carbamoyloxy)methyl]-2-methylpentyl carbamate
micrainin
miltrate
deprol
milpath
equazine-m
meprin (van)
2-metil-2-n-propil-1,3-propanediol dicarbamato [spanish]
miltown 600
meprobamato [italian]
diveron
dea no. 2820
meprobamate and aspirin tablets
einecs 200-337-5
bamate
mepro-analgesic
meprobamatum [inn-latin]
diurnal
meprodiol
2-methyl-2-propyl-1,3-propanediol dicarbamate
meprospan-400
meprospan-200
meprobamat [german]
meprotanum
pathibamate
2-methyl-2-propyltrimethylene carbamate
brn 1788882
pmb-400
hsdb 3117
pmb-200
dormabrol
meprobamato [inn-spanish]
NCGC00091031-01
meprobamic acid
DB00371
D00376
equanil (tn)
miltown (tn)
meprobamate (jan/usp/inn)
CHEMBL979
meprobamate civ
[2-(carbamoyloxymethyl)-2-methylpentyl] carbamate
AKOS003617983
NCGC00091031-02
NCGC00257886-01
tox21_200332
dtxcid903261
cas-57-53-4
dtxsid3023261 ,
tox21_111063
meprovan
my-trans
meproten
MLS003899229
smr000058750
meprobamatum
9i7lny769q ,
meprobamate [usp:inn:ban:jan]
unii-9i7lny769q
meprobamato
meprin (meprobamate)
1,3-propanediol, 2-methyl-2-propyl-, 1,3-dicarbamate
2-metil-2-n-propil-1,3-propanediol dicarbamato
nsc 30418
gtpl7225
({2-[(c-hydroxycarbonimidoyloxy)methyl]-2-methylpentyl}oxy)carboximidic acid
meprobamate [mi]
mepro-aspirin component meprobamate
meprobamate [vandf]
meprobamate [hsdb]
meprobamate [inn]
meprobamate [ep impurity]
meprobamate [mart.]
meprobamate [jan]
meprobamate component of q-gesic
micrainin component meprobamate
q-gesic component meprobamate
meprobamate [usp monograph]
meprobamate civ [usp-rs]
meprobamate component of equagesic
meprobamate [orange book]
meprobamate [who-dd]
meprobamate component of mepro-aspirin
equagesic component meprobamate
meprobamate component of micrainin
SCHEMBL15286
W-105461
mepr
component of milpath (salt/mix)
component of pmb-400 (salt/mix)
meprobamat-petrasch
NPPQSCRMBWNHMW-UHFFFAOYSA-N
microbamat
component of deprol (salt/mix)
component of miltrate (salt/mix)
carb-a-med
pathibamate (salt/mix)
component of milprem (salt/mix)
SR-01000937605-2
sr-01000937605
CHEBI:6761
meprobamate, united states pharmacopeia (usp) reference standard
meprobamate, european pharmacopoeia (ep) reference standard
meprobamate, analytical standard
meprobamate 1.0 mg/ml in methanol
Q418351
diamino 3-methyl-3-propylglutarate; 2-methyl-2-propylpropane-1,3-diyl dicarbamate; [2-(carbamoyloxymethyl)-2-methylpentyl] carbamate
carisoprodol ep impurity d; meprobamate
2-methyl-2-propyl-1,3-propanediyldicarbamate
meprobamato (inn-spanish)
mar bate
tranquilin
marbate
meprobamate (mart.)
meprobamate (ep impurity)
ataraxin
meprobamate (usp monograph)
atraxine
meprobamate compound
2,2-di(carbamoyloxymethyl) pentane
meprobamate civ (usp-rs)
meprobamate (usp:inn:ban:jan)
2-methyl-2n-propyl-propane-1,3-dio-dicarbamate
meprobamatum (inn-latin)
eqiagesic
n05bc01
equinal
meprobamate, 1mg/ml in methanol

Research Excerpts

Overview

Meprobamate is a schedule IV anxiolytic and the primary metabolite of the muscle relaxant carisoprodol.

ExcerptReferenceRelevance
"Meprobamate is a schedule IV anxiolytic and the primary metabolite of the muscle relaxant carisoprodol. "( Assessment of direct gating and allosteric modulatory effects of meprobamate in recombinant GABA(A) receptors.
Dillon, GH; Kumar, M, 2016
)
2.11
"Meprobamate is a carbamate, and the main metabolite of carisoprodol. "( Evaluation of the first immunoassay for the semi-quantitative measurement of meprobamate in human whole blood or plasma using biochip array technology.
Abe, E; Alvarez, JC; Charlier, P; de la Grandmaison, GL; Duverneuil, C; Grassin-Delyle, S; Zouaoui, K, 2012
)
2.05

Effects

ExcerptReferenceRelevance
"Meprobamate has exhibited the most pronounced protective effect."( [Effect of tranquilizers on animal resistance to adequate stimulus exposure of the vestibular apparatus].
Khinchikashvili, NV; Maksimovich, IaB,
)
0.85

Toxicity

ExcerptReferenceRelevance
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36

Pharmacokinetics

ExcerptReferenceRelevance
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" A two-compartment pharmacokinetic model describing carisoprodol metabolism and that of the primary metabolite, meprobamate, was developed to better understand the pharmacokinetics of this drug."( Pharmacokinetic modeling of carisoprodol and meprobamate disposition in adults.
Lewandowski, TA, 2017
)
0.93

Compound-Compound Interactions

ExcerptReferenceRelevance
" A study undertaken in dogs has also been made of the pharmacokinetics of the major nitrated metabolite of PETN when the parent drug is administered with and without meprobamate and diphenhydramine."( A study of the plasma levels of pentaerythritol mononitrate following administration of pentaerythritol tetranitrate in combination with meprobamate and diphenhydramine.
Aylott, RI; Draffan, GH; Gilbert, JD; Sögtrop, HH, 1982
)
0.66
"This hypothesis was tested in an experiment where information about the effect of a drug was combined with administration of an active drug or placebo."( Stimulant and relaxant drugs combined with stimulant and relaxant information: a study of active placebo.
Aamo, T; Flaten, MA; Olsen, H; Sager, G; Simonsen, T; Zahlsen, K, 2004
)
0.32

Bioavailability

The relative bioavailability of 400-mg meprobamate tablets manufactured by 11 different firms was evaluated in two groups of healthy male subjects.

ExcerptReferenceRelevance
"The relative bioavailability of 400-mg meprobamate tablets manufactured by 11 different firms was evaluated in two groups of healthy male subjects."( Relative bioavailability of meprobamate tablets in humans.
Melikian, AP; Meyer, MC; Straughn, AB, 1978
)
0.82
" The bioavailability of meprobamate administered rectally to human volunteers as the marketed preparations DoloVisano Suppositories and Dolo-Visano Suppositories sine codeino, is similar to that observed following oral administration."( The pharmacokinetics of meprobamate following its oral and rectal administration as a series of combinations with diphenhydramine, acetylsalicylic acid, codeine and pentaerythritol tetranitrate.
Aylott, RI; Draffan, GH; Gilbert, JD; Sögtrop, HH, 1984
)
0.88
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The accelerative effect of long-term ethanol administration on meprobamate metabolism may be greatly related to ethanol dosage. It is considered that the accelerative effects reach maximum at blood ethanol concentrations more than 1mg/ml.

ExcerptRelevanceReference
" Plasma meprobamate concentrations at 1, 2, 3, 4, 6, 8, 10, 24, and 32 hr after dosing were determined using a GLC assay."( Relative bioavailability of meprobamate tablets in humans.
Melikian, AP; Meyer, MC; Straughn, AB, 1978
)
0.99
" The records obtained of the effect of the dosage can be seen as a measure of the efficiency of this method."( [The influence of centrally acting drugs on flicker fusion frequency].
Feller, K; Graupner, K; Kálmán, E; von Littrow, C, 1975
)
0.25
" Therefore, this screening method is able to detect the presence of drugs even a therapeutic-level dosages, with the exception of compounds such as haloperidol, which have extremely low therapeutic dosage levels."( [Screening of drugs and chemicals by wide-bore capillary gas chromatography. II. Detection of drugs and chemicals in the blood].
Fujiwara, Y; Fukuma, Y; Hara, K; Hieda, Y; Kageura, M; Kashimura, S; Morinaga, M; Takamoto, M, 1990
)
0.28
" Thus, accelerative effect of long-term ethanol administration on meprobamate metabolism may be greatly related to ethanol dosage and it is considered that the accelerative effects reach maximum at blood ethanol concentrations more than 1mg/ml."( Experimental studies on effects of long-term ethanol administration on meprobamate elimination from blood.
Moriya, F; Nanikawa, R, 1989
)
0.75
" Dose-response curves for this effect are reported for chlordiazepoxide, diazepam and meprobamate."( Septal driving of hippocampal theta rhythm: role of gamma-aminobutyrate-benzodiazepine receptor complex in mediating effects of anxiolytics.
Gray, JA; McNaughton, N; Mellanby, J; Nordeen, H; Nutt, D; Quintero, S; Thompson, MR, 1985
)
0.49
" Due to many different pharmacokinetic properties, no perfect rules for dosage in acute or chronic hemodialysis exist."( Tranquilizers, analgetics and antidepressants in patients treated with hemodialysis.
Forycki, Z; Ibe, K; Martens, F; Thalhofer, S, 1985
)
0.27
" Generally, both LZ and MEP produced comparable dose-related effects; LZ had a more rapid onset of action and on several measures showed a more shallow dose-response curve than MEP."( Lorazepam and meprobamate dose effects in humans: behavioral effects and abuse liability.
Griffiths, RR; Roache, JD, 1987
)
0.63
" The effects on the overall response and the induction and elicitation phases were evaluated, using two alternative dosage schedules for each agent."( Different effects of psychotropic drugs on delayed hypersensitivity responses in mice.
Descotes, J; Evreux, JC; Tedone, R, 1985
)
0.27
"A simple model system for the behavioral actions of benzodiazepines is analyzed for its dose-response predictiveness, using several benzodiazepines, and for its pharmacological specificity, using other non-anxiolytic classes of psychoactive drugs."( Neuropharmacologic specificity of a simple animal model for the behavioral actions of benzodiazepines.
Crawley, JN, 1981
)
0.26
" Administration of meprobamate with oral sultopride in a high dosage (2 g per day) was promptly followed by an improvement in the patient's condition."( [The use of a sedative neuroleptic agent, sultopride, in posttraumatic Korsakoff syndrome in a young adult].
Cornier, P, 1983
)
0.59
" PTZ test was influenced by meprobamate in a fairly low dosage (ED50 66 mg/kg), but for felbamate no clearly dose-related effect could be shown up to 150 mg/kg."( Felbamate and meprobamate: a comparison of their anticonvulsant properties.
Bartels, I; Frey, HH, 1997
)
0.95
" Triazolam, meprobamate, and butabarbital showed comparable negative dose-response slopes on the objective measures."( Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital.
Busto, UE; Greenblatt, DJ; Kaplan, HL; Sellers, EM; Zawertailo, LA, 2003
)
0.94
" This result indicates a gene dosage effect where the carisoprodol : meprobamate ratio reflects the number of active CYP2C19 alleles."( Association between blood carisoprodol:meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects?
Bramness, JG; Fauske, L; Grung, M; Molven, A; Mørland, J; Skurtveit, S; Steen, VM, 2003
)
0.82
"Further evaluation of this drug is essential with emphasis on establishment of pediatric dosage schedules and to further confirm reliability."( Newer concepts in the management of tetanus.
COCK, TC, 1961
)
0.24
"The facility of implementation reached by solid-state nuclear magnetic resonance (ssNMR) spectroscopy makes this technique increasingly popular in pharmaceutical sciences, and more specifically for the dosage of active principles in pharmaceutical formulations, since about 80% of the formulations currently available on the market are present in the solid form."( Improved solid-state NMR quantifications of active principles in pharmaceutical formulations.
Caldarelli, S; Delaurent, C; Sanchez, S; Viel, S; Ziarelli, F, 2008
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Capecitabine Action Pathway58
Capecitabine Metabolism Pathway58

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID886
GLI family zinc finger 3Homo sapiens (human)Potency25.81350.000714.592883.7951AID1259369
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency51.98340.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency72.75220.003041.611522,387.1992AID1159553
retinoid X nuclear receptor alphaHomo sapiens (human)Potency39.81070.000817.505159.3239AID588544
pregnane X nuclear receptorHomo sapiens (human)Potency61.14960.005428.02631,258.9301AID1346982; AID720659
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency31.62280.01789.637444.6684AID588834
lamin isoform A-delta10Homo sapiens (human)Potency0.44670.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (74)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1136333Anxiolytic activity in po dosed rat assessed as protection against pentylenetetrazole-induced seizures administered in 2% starch1978Journal of medicinal chemistry, Oct, Volume: 21, Issue:10
Derivatives of 1,2,3,11a-tetrahydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-5,11(10H)-dione as anxiolytic agents.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1146458Neuroleptic activity in ip dosed mouse assessed as blockade of corneal reflex by measuring failure to blink1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
A series of hexahydro[1,4]oxazino[3,4-a]isoquinolines as potential neuroleptics.
AID468443Inhibition of human FAAH at 1 uM2009Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23
Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1123421Anticonvulsant activity in po dosed mouse assessed as reduction of pentylenetetrazole-induced seizures1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
The benzodiazepine story.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1134094Central nervous system activity in ip dosed rat assessed as dose required to cause depression by measuring decreased motor activity1977Journal of medicinal chemistry, May, Volume: 20, Issue:5
Synthesis and central nervous system activity of 2-arylidene-4-aminoalkyl-2H-1,4-benzoxazin-3(4H)-ones and related compounds.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID114116Anticonvulsant activity was evaluated by maximal electroshock induced convulsion test after subcutaneous administration1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Synthesis and anticonvulsant activity of some substituted lactams and amides.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1134095Central nervous system activity in ip dosed rat assessed as dose required to cause decreased reflex action by measuring decreased grip strength1977Journal of medicinal chemistry, May, Volume: 20, Issue:5
Synthesis and central nervous system activity of 2-arylidene-4-aminoalkyl-2H-1,4-benzoxazin-3(4H)-ones and related compounds.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID40662in vitro inhibition of [3H]diazepam binding against rat Benzodiazepine receptor1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Synthesis and anxiolytic activity of 6-(substituted-phenyl)-1,2,4-triazolo[4,3-b]pyridazines.
AID1123422Anticonvulsant activity in po dosed mouse assessed as reduction of maximal electroshock-induced seizures1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
The benzodiazepine story.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1123419Induction of taming effect in po dosed mouse by foot shock method1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
The benzodiazepine story.
AID1123826Central nervous system activity in ip dosed rat assessed as induction of depressant1979Journal of medicinal chemistry, Feb, Volume: 22, Issue:2
Bicyclic pyrazolines, potential central nervous system depressants and antiinflammatory agents.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1146455Neuroleptic activity in ip dosed mouse assessed as blockade of righting reflex by measuring failure to right to normal position measured for 30 secs1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
A series of hexahydro[1,4]oxazino[3,4-a]isoquinolines as potential neuroleptics.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID409951Inhibition of human liver MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1123420Muscle relaxing activity in po dosed cat1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
The benzodiazepine story.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1186830Fraction unbound in mouse brain2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Rational use of plasma protein and tissue binding data in drug design.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1123418Induction of muscle relaxation/sedation in po dosed mouse by inclined screen test1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
The benzodiazepine story.
AID679760TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: ? uM, Meprobamate: 100 uM) in MDR1-expressing MDCKII cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
AID1146456Neuroleptic activity in ip dosed mouse assessed as blockade of traction reflex by measuring failure to grasp wire with hind paws measured for 5 secs1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
A series of hexahydro[1,4]oxazino[3,4-a]isoquinolines as potential neuroleptics.
AID40663In vitro inhibition of [3H]diazepam binding towards Benzodiazepine receptor at 1 uM1981Journal of medicinal chemistry, May, Volume: 24, Issue:5
Synthesis and anxiolytic activity of 6-(substituted-phenyl)-1,2,4-triazolo[4,3-b]pyridazines.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID114118Anticonvulsant activity was evaluated by metrazole-induced convulsion test after subcutaneous administration1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Synthesis and anticonvulsant activity of some substituted lactams and amides.
AID1146457Neuroleptic activity in ip dosed mouse assessed as blockade of prehensile reflex by measuring failure to hang measured for 5 secs1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
A series of hexahydro[1,4]oxazino[3,4-a]isoquinolines as potential neuroleptics.
AID681116TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing MDCKII cells2002The Journal of pharmacology and experimental therapeutics, Dec, Volume: 303, Issue:3
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1123423Anticonvulsant activity in po dosed mouse assessed as reduction of minimal electroshock-induced seizures1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
The benzodiazepine story.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID121845Anticonvulsant activity was evaluated by rotarod toxicity test after subcutaneous administration.1984Journal of medicinal chemistry, Feb, Volume: 27, Issue:2
Synthesis and anticonvulsant activity of some substituted lactams and amides.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID409946Inhibition of human recombinant MAOB at 100 uM by fluorimetric method2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,076)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901944 (93.64)18.7374
1990's37 (1.78)18.2507
2000's44 (2.12)29.6817
2010's47 (2.26)24.3611
2020's4 (0.19)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 65.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index65.55 (24.57)
Research Supply Index7.80 (2.92)
Research Growth Index4.34 (4.65)
Search Engine Demand Index116.62 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (65.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials125 (5.40%)5.53%
Reviews64 (2.77%)6.00%
Case Studies106 (4.58%)4.05%
Observational0 (0.00%)0.25%
Other2,018 (87.25%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]